Prolia (Denosumab) Cost in Mississippi 2026: Pricing, Insurance, and Savings Options

Denosumab is a monoclonal antibody sold under two brand names for two different uses: Prolia (60 mg, injected once every six months) is FDA-approved for postmenopausal osteoporosis, bone loss from hormone-ablation therapy, and glucocorticoid-induced osteoporosis. Xgeva (120 mg, dosed monthly) is a separate FDA-approved formulation used in oncology for skeletal-related events. This article is about Prolia and osteoporosis-related cost questions. The two products are not interchangeable, and pricing questions for one do not apply to the other.

The direct answer: what a Mississippi patient actually pays for Prolia depends far more on insurance pathway than on the manufacturer's list price. Cash-pay patients face the full list price roughly every six months; most commercially insured patients pay a specialty-tier copay after prior authorization; Medicare Part B beneficiaries pay 20% coinsurance unless a Medigap plan covers it; and Mississippi Medicaid coverage for osteoporosis indications should be confirmed directly with the state program, because formulary status changes and this article cannot certify Medicaid's current preferred-drug-list decision as of any specific 2026 date. Every dollar figure below should be treated as an illustrative range, not a quoted price, until verified against a current source.

What does Prolia actually cost, and why do quoted prices vary so much?

Amgen sets a manufacturer list price for Prolia, and that list price is a public, checkable figure that Amgen and major drug-pricing databases publish and update periodically. List price is not what most patients pay. It is the starting point before insurance discounts, pharmacy contracts, site-of-care fees, and manufacturer savings programs are applied.

Three separate cost layers apply to Prolia in Mississippi, and they should not be confused with each other:

1. The drug itself, either dispensed through a pharmacy (patient self-pay or commercial insurance) or purchased and billed by a physician's office under a buy-and-bill model, which is common for Medicare Part B patients and billed under a specific HCPCS code.
2. Administration and monitoring, an injection fee if given in-office or via home health, plus periodic lab work (serum calcium and vitamin D status are relevant given denosumab's hypocalcemia risk).
3. Site-of-care markup, hospital outpatient departments frequently bill differently than a physician's private office or a retail pharmacy, and Mississippi has both large hospital systems and independent practices that may quote different total costs for the same drug.

Because pricing at each layer changes without notice and varies by payer contract, this article does not publish a single dollar figure as current. Readers who need an exact number should get a direct quote from the dispensing pharmacy or billing office and confirm it against Amgen's published list price for the current date.

Does Mississippi Medicaid cover Prolia for osteoporosis?

Medicaid coverage of specific drugs is set at the state level through a preferred drug list (PDL) that is revised periodically, so any claim about "Mississippi Medicaid does or does not cover Prolia" is a date-sensitive fact, not a stable one. What is stable and can be stated with confidence: Medicaid programs nationally tend to favor generic oral bisphosphonates (alendronate, risedronate) as first-line osteoporosis therapy because of their low cost, and many state Medicaid programs require documented bisphosphonate intolerance or a contraindication before approving a biologic like denosumab through prior authorization.

Readers on Mississippi Medicaid should confirm current Prolia coverage status directly with the Mississippi Division of Medicaid or their managed care organization, since this is exactly the kind of fact that goes stale within months. A prescriber's office can typically initiate a prior authorization request and will know the current documentation requirements.

Which commercial insurers and Medicare pathways apply in Mississippi?

Commercial insurers generally cover Prolia as a specialty-tier drug once prior authorization criteria are met, most commonly a T-score threshold, a prior fragility fracture, or a high estimated 10-year fracture risk, often combined with a step-therapy requirement to try an oral bisphosphonate first. Blue Cross Blue Shield of Mississippi is the state's largest commercial insurer and, like other insurers offering plans in the state, structures specialty-drug cost-sharing through its own formulary tiers; exact copay amounts and step-therapy rules are plan-specific and change at renewal, so they should be confirmed against the member's current summary of benefits rather than assumed from a general figure.

Medicare Part B covers Prolia for eligible beneficiaries after the annual Part B deductible, with the beneficiary responsible for standard Part B coinsurance unless a Medigap or other supplemental plan covers the remainder. The exact deductible amount and coinsurance percentage are set annually by CMS and should be confirmed for the current year rather than carried over from a prior year's figure.

How does the Amgen savings card work, and who qualifies?

Amgen operates a savings card program for commercially insured patients that can reduce out-of-pocket cost per injection, subject to an annual benefit cap that Amgen sets and periodically adjusts. Patients enrolled in any federal or state health program (Medicare, Medicaid, TRICARE, VA) are categorically ineligible for manufacturer copay cards under federal anti-kickback rules that apply broadly to pharma savings programs, not just this one. Amgen also operates a separate patient-assistance foundation for uninsured or underinsured patients meeting income criteria.

Because savings-card terms, caps, and eligibility rules change, readers should verify current terms directly on Amgen's Prolia patient support materials or by calling the program before assuming a specific dollar benefit applies to them.

Is compounded denosumab a real option in Mississippi, and is it a good idea?

Mississippi-licensed 503A compounding pharmacies operate under a federal legal framework, the Drug Quality and Security Act, which distinguishes patient-specific 503A compounding from the larger-batch 503B outsourcing facility model. That legal framework exists and is stable.

What is not established is that compounded denosumab is widely available or advisable. Denosumab is a monoclonal antibody, not a small-molecule drug, and biologics require cold-chain handling and sterile manufacturing controls that most community compounding pharmacies are not equipped to validate. Regulators have repeatedly noted that compounded drugs, including complex biologics, are not FDA-approved and do not undergo the same premarket testing for potency, purity, sterility, and identity as manufactured products. A lower advertised price for a compounded biologic does not carry the same evidence of manufacturing consistency as the FDA-approved product, and this is a material safety consideration, not just a cost one.

Anyone considering a compounded formulation should verify the pharmacy's current Mississippi Board of Pharmacy license, ask specifically about sterility testing and potency verification for biologic preparations, and discuss the tradeoff with the prescribing clinician rather than choosing based on price alone.

What happens if Prolia is stopped, and why does that matter for cost decisions?

This is the most clinically important fact on this page and it is well established: stopping denosumab is associated with a rebound loss of bone mineral density and, in some patients, an increased risk of multiple vertebral fractures within roughly one to two years of the last dose. This effect is described in the FDA-approved prescribing information and has been reported in extension follow-up of the pivotal osteoporosis trial. It means denosumab should not be discontinued, switched to a cheaper compounded version, or interrupted for cost reasons without a plan, usually a bisphosphonate, to maintain bone density afterward. Anyone considering stopping Prolia for cost reasons, including switching to a compounded product with uncertain potency, should raise the rebound-fracture risk with their prescriber before making that decision, since an interruption in effective dosing carries a distinct and separate risk from the drug's cost.

How Prolia compares with other osteoporosis treatments on cost and evidence

This table reflects relative cost positioning and general evidence categories, not exact dollar amounts, because exact prices are payer- and date-specific.

Evidence boundary: what is established, what is plausible, and what needs verification

Established: Prolia is FDA-approved for the osteoporosis indications listed above with a twice-yearly dosing schedule; denosumab carries a documented rebound bone-loss and fracture risk after discontinuation; 503A compounding pharmacies operate under a specific federal legal framework distinct from 503B facilities; oral bisphosphonates are generally the lowest-cost, most widely covered first-line osteoporosis therapy.

Plausible but not verified here: specific current list prices, specific Mississippi Medicaid coverage determinations, specific commercial insurer copay tiers, specific savings-card caps, and specific compounding-pharmacy availability in Mississippi. These are all real and answerable questions, but they change on time scales of months, not years, and none of them should be treated as fixed facts from this page.

Not established: that a compounded denosumab preparation matches the potency, purity, or clinical outcomes of FDA-approved Prolia. No published evidence establishes equivalence, and the FDA's general caution about compounded biologics applies.

If a bone density result, fracture history, or treatment-switch decision is involved, that discussion belongs with a prescribing clinician who can review the individual's labs and DXA results, not a general cost page.

Verification checklist: stable facts vs. facts that expire

Use this to separate what a Mississippi reader can rely on today from what needs a fresh check before making a decision.

Stable (federal/clinical, unlikely to change quickly):

• Prolia's FDA-approved indications and twice-yearly dosing schedule
• The rebound bone-loss/fracture risk after stopping denosumab
• The legal distinction between 503A compounding pharmacies and 503B outsourcing facilities
• The general clinical hierarchy (bisphosphonates as first-line, denosumab/anabolic agents for higher-risk or bisphosphonate-intolerant patients)

Date-sensitive (verify before relying on it):

• Current Amgen list price for Prolia
• Current Mississippi Medicaid preferred-drug-list status for denosumab
• The specific insurer's current prior-authorization criteria and specialty-tier copay
• Current Medicare Part B deductible and coinsurance amounts for the plan year
• Current Amgen savings-card eligibility rules and annual cap
• Whether a specific 503A pharmacy in Mississippi currently compounds denosumab and holds an active state license
• Any cash-pay discount card's actual negotiated price at the specific pharmacy

Confirm date-sensitive items with the pharmacy, insurer, or state Medicaid office directly, and note the date you checked, since these facts have a short shelf life.

When to seek urgent care rather than manage this by cost alone

Cost and coverage questions should never delay evaluation of symptoms that suggest a fracture, severe hypocalcemia (muscle cramps, tingling, seizures), or an unusual femur pain that can signal an atypical femoral fracture associated with long-term antiresorptive therapy. Those situations require prompt medical evaluation regardless of insurance status.

Note for editorial review: the original draft's PubMed citations (FREEDOM, FIT, HORIZON-PFT, ARCH trial IDs and journal citations) could not be verified against the primary literature during this revision and have been removed rather than carried forward with an unverified locator. If specific trial statistics (fracture-risk-reduction percentages) are needed on this page, they should be re-sourced and cited directly from the original published trials before publication. All Mississippi-specific dollar figures, Medicaid formulary status, insurer copay tiers, and program eligibility rules in the prior draft were unsourced and have been converted to a verification checklist rather than presented as current facts.